



**HAL**  
open science

## What lessons can be learned about asthma phenotypes in children from cohort studies?

Jocelyne Just, Flore Amat, P Saint-Pierre, R Gouvis-Echraghi, N Guillemot,  
T Guiddir, R Couderc, Isabella Annesi-Maesano

► **To cite this version:**

Jocelyne Just, Flore Amat, P Saint-Pierre, R Gouvis-Echraghi, N Guillemot, et al.. What lessons can be learned about asthma phenotypes in children from cohort studies?. *Pediatric Allergy and Immunology*, 2015, 26 (4), pp.300-305. 10.1111/pai.12359 . hal-01166988

**HAL Id: hal-01166988**

**<https://hal.sorbonne-universite.fr/hal-01166988>**

Submitted on 23 Jun 2015

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

1 **What lessons can be learned about asthma phenotypes in children**  
2 **from cohort studies?**

3 **J Just<sup>1,2</sup>, F Amat<sup>1,2</sup>, P Saint Pierre<sup>3</sup>, R Gouvis-Echraghi<sup>1</sup>, N Guillemot<sup>1,2</sup>, T**  
4 **Guiddir<sup>1,2</sup>, R Couderc<sup>4</sup>, I Annesi Maesano<sup>2</sup>**

5

6 <sup>1</sup>Allergology department, Centre de l'Asthme et des Allergies. Hôpital d'Enfants  
7 Armand-Trousseau (APHP) –

8 <sup>2</sup>Sorbonne Universités, UPMC Univ Paris 06, UMR\_S 1136, Institut Pierre Louis  
9 d'Epidémiologie et de Santé Publique, Equipe EPAR, F-75013, PARIS 75571 Cedex

10 <sup>3</sup>Laboratoire de statistiques théoriques et appliquées, Université Pierre et Marie Curie -  
11 Paris 06, 4 place Jussieu, 75252 PARIS cedex 05, France.

12 <sup>4</sup>Service de biochimie et biologie moléculaire, Hôpital d'Enfants Armand-Trousseau -  
13 26, Avenue du Dr. Arnold Netter, 75571 PARIS Cedex 12 – UPMC Univ Paris 06.  
14 France.

15 Word (4780 /4500)

16 Ref (43/75)

17

18

19 Address for correspondence:

20 **Pr. Jocelyne JUST**

21 Centre de l'Asthme et des Allergies. Hôpital d'Enfants Armand-Trousseau (APHP) -  
22 26, Avenue du Dr. Arnold Netter, 75571 PARIS Cedex 12. France.

23 Tel. +33 1 44 73 63 17

24 Fax: +33 1 44 73 66 35

25 E-mail: [jocelyne.just@trs.aphp.fr](mailto:jocelyne.just@trs.aphp.fr)

26

27

28 **Abstract**

29 “Phenotyping” asthma by multivariate analyses and more recently by unsupervised  
30 analysis has been performed in children cohorts. We describe the key findings that  
31 have emerged from these cohorts. In very young children 3 wheeze phenotypes seem  
32 to exist: the mild episodic viral wheeze phenotype, the severe atopic wheeze and more  
33 infrequently encountered the severe nonatopic wheeze. Early onset of allergy in  
34 asthma (more frequently encountered in boys) is associated with poor prognosis unlike  
35 the severe non-atopic wheeze phenotype with a female predominance. The prognosis  
36 of the severe nonatopic wheeze depends on time of onset (early or late) of allergic  
37 expression. At school age, the risk of severe asthmatic exacerbations is associated with  
38 eosinophil predominant inflammation frequently related to allergic asthma, whereas  
39 neutrophil inflammation is associated with moderate-to-severe asthma with poorer  
40 lung function. Nevertheless, Allergic asthma is also a heterogeneous disease with  
41 severe allergic phenotype strongly associated with atopic dermatitis and very  
42 high eosinophil-driven inflammatory markers. Further studies are required to find non-  
43 invasive biological markers to better define wheezing phenotypes in very young  
44 children associated with an elevated risk of developing severe asthma with a view to  
45 personalizing treatment.

46

**47 Introduction**

48 Asthma is the most common disease during childhood. It affects 200–300 million  
49 people worldwide, and its prevalence has increased over the past few decades<sup>1</sup>. It is a  
50 heterogeneous disease in terms of triggers, severity, inflammation and age of onset<sup>2</sup>.  
51 To date, asthma classification has mainly been related to asthma severity: it is  
52 generally accepted that phenotypes related to asthma severity follow a track during  
53 childhood and even during the whole of life<sup>3</sup>. This observation supports the notion that  
54 phenotypes defined by asthma severity remain stable.

55 Asthma severity is also an important parameter because the major healthcare burden of  
56 this disease is related to severe asthma. Nevertheless, severe asthma includes multiple  
57 features and it is important to distinguish between the different severe phenotypes to  
58 determine targeted and effective treatment<sup>4</sup>.

59 Anti-inflammatory treatment is the pedestal of asthma treatment but there is ongoing  
60 debate about whether children, especially preschool children, should be treated with  
61 continuous or intermittent inhaled corticosteroid treatment. On the other hand,  
62 uncontrolled asthma despite high levels of controlled medication should be treated  
63 with an additional treatment such as an anti-IgE<sup>5</sup> or various anti-cytokine treatments.

64 There is currently growing evidence that personalized medicine based on phenotypes  
65 and endophenotypes (characterized by physiopathological pathways) is important in  
66 the management of all chronic diseases<sup>6</sup> For all these reasons, and especially to  
67 contribute to decreasing the burden of the disease, phenotypes deserve to be described  
68 in asthma.

69 Against this background of “phenotyping” asthma, multivariate analyses and, more  
70 recently, unsupervised analyses have been performed in birth cohorts<sup>789101112131415</sup>. In  
71 the same manner, phenotyping analyses have also been performed in cohorts of

72 children comprising moderate to severe asthma phenotypes<sup>1617181920212223</sup>. In relation to  
73 these data, it appears that age of onset, hyperresponsiveness, asthma control under  
74 treatment and multiple sensitizations are important parameters to define phenotypes of  
75 asthma during childhood.

76 In this article we highlight the main results, which have emerged from these cohorts in  
77 preschool then in school age wheezers

78

79 ***In very young children, severe asthma phenotypes exist and are related to gender***  
80 ***(Table n•1)*** The Pollution and Asthma Risk an Infant Study (PARIS), a birth cohort  
81 composed of 3500 full-term newborns recruited in five public Parisian maternity  
82 hospitals in Paris and its close suburbs, described wheezer phenotypes<sup>24</sup>: severe atopic  
83 wheezers and non-atopic severe wheezers as well as a mild nonatopic wheezer  
84 phenotype. Trousseau Asthma Program (TAP) cohorts are independent cohorts of  
85 several hundred consecutive children explored in a cross-sectional and prospective  
86 manner by unsupervised analysis. In a TAP cohort study of 551 early wheezers with  
87 an average age of 18 months described similar asthma phenotypes by cluster  
88 analysis: “*Mild Episodic Viral Wheeze*” (*EVW*) and “*Atopic Multiple-Trigger*” (*AMT*)  
89 and “*Non-atopic uncontrolled-wheeze*” (*NAUW*)<sup>14</sup> (Fig 1). These phenotypes were  
90 validated by another independent TAP cohort<sup>15</sup> which also applied a new approach  
91 including exhaled nitric oxide (FeNO) determinants together with severity and atopy  
92 by cluster analysis. Furthermore

93 *EVW* consisted of children with wheeze related to cold only, mild disease. These  
94 findings are consistent with The Tucson Children's Respiratory Study. This birth  
95 cohort is a long-term, longitudinal, prospective study of the risk factors for acute lower  
96 respiratory tract illnesses in early childhood and for chronic obstructive airways  
97 disease in later life. It includes 1,246 newborns enrolled between May 1980 and  
98 January 1984<sup>25</sup>. For the first time these authors described early transient wheeze with  
99 rare episodes of wheeze apart from colds in infancy compared to persistent  
100 wheezers<sup>26</sup>. In the same manner, Spycher *et al* <sup>27</sup>. in two independent cohorts (nested  
101 samples of total population of 1,650 white children recruited in 1990 at the age of 0–5  
102 years in Leicestershire, UK) showed a phenotype with mild, virus-triggered symptoms  
103 wheeze. The *AMT* phenotype, includes more children with allergic diseases such as

104 eczema, allergic rhinitis (AR) food allergy and more specific IgE positivity and a  
105 higher proportion of elevated values for total IgE. This phenotype is associated with  
106 severe wheezing disease, defined by a greater percentage of multiple trigger wheezes  
107 (*MTW*). The *AMT* phenotype is comparable to phenotypes identified by using other  
108 approaches. For example, in the Avon Longitudinal Study of Parents and Children  
109 (ALSPAC)<sup>6</sup>, a birth cohort in which the children of 14 541 pregnancies were recruited  
110 antenatally between 1990–92, two phenotypes characterized by early and  
111 intermediate-onset of wheeze persisting during childhood were characterized by  
112 allergy features (with skin prick test positivity) and severity of the disease (with  
113 bronchial hyperresponsiveness and reduced lung function)<sup>28</sup>. This description was also  
114 confirmed across two independent cohorts of children previously described by  
115 Spycher *et al*<sup>21</sup>. The TAP cohort found that more boys fell into the *AMT* group. This  
116 might be related to the well-known association between male gender and allergic  
117 diseases<sup>2930</sup>. In a British birth cohort, The National Asthma Campaign Manchester  
118 Asthma and Allergy Study (MAAS cohort) parents were screened at ‘booking’  
119 antenatal visits between October 1995 and July 1997. A total of 3,618 mothers and  
120 2,172 fathers underwent skin-prick testing and newborns were allocated to allergic risk  
121 groups according to parental atopic status. The main result of this cohort was the  
122 impact of early onset allergy on asthma prognosis. Effectively, Belgrave *et al*.<sup>31</sup>  
123 showed that children with frequent asthma exacerbations and multiple early atopy are  
124 at risk of a progressive loss of lung function from 3 to 11 years and this effect is also  
125 more marked in boys.

126 *NAUW* was characterized mainly by moderate to severe disease and uncontrolled  
127 wheeze despite high doses of ICS, a higher proportion of parental asthma and higher  
128 ferritine values. This phenotype has been less described by other teams. However,



129 Spycher *et al.*<sup>21</sup>, showed an intermediate phenotype between the atopic persistent and  
130 the viral wheeze phenotype in terms of prognosis in preadolescence.

131 Moreover, in the TAP cohort the *NAUW* phenotype was only encountered in girls.

132 Isozaki *et al.*<sup>32</sup> demonstrated a gender difference in phenotypes with atopic wheezing  
133 more frequently encountered in boys and non-allergic wheezing resistant to treatment  
134 more prevalent in girls. This phenotype has been known for a long time in adults and  
135 is described as 'Intrinsic asthma' with a female predominance though the aetiology is  
136 still not understood<sup>33</sup>.

137 In the TAP cohort, with only two parameters related to atopy and asthma severity (i.e.  
138 total IgE and asthma severity), 90% of boys and 83% of girls were assigned to the  
139 appropriate cluster (Fig 2). This result underlines the impact of atopy but also of the  
140 “intrinsic” aetiology in disease severity, with a higher percentage of boys in severe  
141 atopic phenotypes and girls in severe non-atopic phenotypes.

142

143 ***Stability of asthma phenotypes in very young children during preschool age depends***  
144 ***on allergic expression (Table n°1)***

145 Several rules have been developed to predict whether preschool children will have  
146 asthma at school age such as the stringent and loose forms of the Asthma Predictive  
147 Index (API) in the Tucson Cohort<sup>34</sup>. The Prevention and Incidence of Asthma and  
148 Mite Allergy (PIAMA) is a birth cohort study initiated in 1996 which enrolled  
149 children born to allergic mothers in a double-blind placebo-controlled trial to evaluate  
150 the use of mite-impermeable mattress and pillow covers<sup>35</sup>. In this cohort, the API  
151 scores were externally validated with predictions comparable to the original Tucson  
152 study. However, these prediction rules are difficult to apply in clinical practice  
153 because of an overall low positive predictive value<sup>36</sup>.

154 Another approach of the TAP cohort was to investigate if prospectively defined  
155 phenotypes could have a different course during childhood and thus improve  
156 prediction of the course of asthma (Fig 3)<sup>17</sup>. This study revealed a good prognosis for  
157 children classified as having the *EVW* phenotype: at 5 years old 69% were still in the  
158 *EVW* group or were asymptomatic. This finding is in accordance with many other  
159 studies which demonstrate that recurrent viral induced wheeze has a good prognosis  
160 with a low risk of asthma<sup>37</sup> or mild asthma. Spycher *et al*<sup>21</sup> in particular noted that  
161 despite mild symptoms in early life, children with transient wheeze were more likely  
162 than controls to continue to have current wheeze and use bronchodilators in  
163 preadolescence. This finding underlines the fact that remission  
164 can occur in this phenotype, a fact which is important for the clinician in the  
165 management of early wheezing.

166 The prognosis of the initial severe phenotypes (*AMT* and *NAUW*) is worse than for  
167 *EVW*. This finding is in accordance with the notion of tracking asthma severity during  
168 childhood<sup>38</sup>. None of the children in the *AMT* phenotype became asymptomatic at 5  
169 years and more than half of *NAUW* children were still severe at 5 years (Fig 3). This  
170 poor prognosis of allergic asthma with early onset has already been described in  
171 numerous prospective birth cohorts<sup>203940</sup>. The MAAS<sup>4142</sup> demonstrated that atopy, and  
172 especially early onset of multiple sensitizations, increases the risk of persistence of  
173 asthma with severe exacerbations during childhood. In contrast, only Spycher *et al*.<sup>21</sup>  
174 found a third wheeze phenotype in both their cohorts – identified as intermediate  
175 between the atopic persistent and the viral wheeze phenotype – associated with a poor  
176 prognosis in preadolescence similarly to the TAP findings for the *NAUW* group.  
177 Possibly, this phenotype is associated with persistent wheezing during preschool and  
178 school age in relation with late-onset atopy.

179 More globally, the lesson to retain about prognosis of the early wheezer is that  
180 changes observed in each initial phenotype in preschool aged children depend not only  
181 on the expression of allergy but also on the time of onset (early or late). Finally,  
182 although none of the phenotypes identified in the TAP corresponded to the GINA  
183 definition of asthma severity, it is worth noting that their most recent guidelines<sup>43</sup> have  
184 approved a “phenotyping approach” in asthma management by referencing the TAP  
185 article<sup>17</sup>.

186

187 *Asthma severity at school age depends on inflammatory cellular type (Table n°1 et*  
188 *n°2)*

189 Asthma in children is highly heterogeneous and is related not only to lung function  
190 and atopy but also to systemic inflammation. Another TAP cohort recruited 309  
191 children of school age and identified three independent clusters of asthma in a cluster  
192 analysis applied to 15 variables<sup>44</sup>.

193 The “*Asthma with multiple allergic sensitizations*” cluster was more atopic, with more  
194 frequent severe exacerbations but relatively normal lung function. This type of severe  
195 asthma is associated with an inflammation predominantly of “allergic type” (with  
196 eosinophil and basophil cells) in combination with multiple allergic sensitizations and  
197 elevated total IgE. Many studies, mainly in children, have confirmed that asthma at  
198 risk of severe exacerbations or difficult to control is associated with allergic asthma<sup>45</sup>.

199 The “*Severe asthma with bronchial obstruction*” cluster was characterized by the  
200 lowest lung function and more blood neutrophils, IgG and IgA but less atopy. The  
201 children were also older and had a higher BMI. Other studies have shown an  
202 association between the severity of asthma and neutrophilic inflammation detected by  
203 induced sputum in particular in adult<sup>46,47</sup> The TAP results underline that neutrophilic

204 asthma exists also in children with unknown aetiology<sup>38</sup>. This finding supports those  
205 of the Epidemiological study on the Genetics and Environment of Asthma, bronchial  
206 hyperresponsiveness and atopy (EGEA). The EGEA family sample consisted of 388  
207 French nuclear families that included 253 families ascertained through offspring with  
208 asthma (one offspring proband in 90% of families and two in the remainder) and 135  
209 families ascertained through a parent with asthma. EGEA asthma phenotypes showed  
210 that the phenotype of “active treated allergic childhood-onset asthma” is associated  
211 with blood eosinophilia, while "active treated adult-onset asthma" is associated to  
212 blood neutrophils<sup>48</sup>. Another group linked inflammation to asthma severity. The  
213 Severe Asthma Research Program (SARP) funded by the The National Heart, Lung,  
214 and Blood Institute (NHLBI) recruited subjects with asthma of all ages who met the  
215 ATS workshop definition of severe asthma. An additional group of subjects with  
216 asthma that did not meet the criteria for severe asthma (not severe) was also studied. In  
217 the same manner as in previous studies, a multivariate approach identified a severity  
218 spectrum related to sputum cellular inflammation from mild-to moderate allergic  
219 asthma with minimal or eosinophil predominant inflammation to moderate-to-severe  
220 asthma with neutrophil-predominant or mixed granulocytic inflammation<sup>49</sup>.

221

222 ***Allergic asthma is a heterogeneous disease (Table n°2)***

223 Allergy expression defines the prognosis of asthma during childhood but the problem  
224 is how should atopy be defined? Atopy depends on allergic sensitization (single or  
225 multiple but also the type of allergen and the date of onset of sensitization) and the  
226 association with allergic comorbidities (AR, eczema, food allergy).

227 In a recent article<sup>16</sup>, a TAP cohort study performed in 125 children of school age with  
228 allergic asthma described four phenotypes.

229 The “*House dust mite (HDM) Sensitization and Mild Asthma*” phenotype, 98% of  
230 whom were monosensitized and had mild asthma (74% of cases). In a previous study,  
231 we had described a similar phenotype of asthma with few allergic sensitizations and  
232 mild asthma<sup>38</sup>. Moore *et al.*<sup>50</sup> also defined a large cluster (82% of the study  
233 population) of adults with early-onset mild atopic asthma. The Childhood Asthma  
234 Prevention Study (CAPS)<sup>7</sup> included pregnant women whose unborn children were at  
235 high risk of developing asthma because of a parent or a sibling with a current  
236 diagnosis of asthma or frequent wheeze recruited from the antenatal clinics of six  
237 hospitals in Sydney, Australia. Six hundred and sixteen women were enrolled in the  
238 main trial between September 1997 and December 1999<sup>51</sup> Both the CAPS and MAAS  
239 cohorts<sup>30</sup> as well as the TAP cohort defined an HDM monosensitized population which  
240 confers a better prognosis of asthma than children with multiple sensitizations.

241 In the TAP cohort, the “*Pollen Sensitization with Severe Exacerbations*” phenotype  
242 comprised 92% of children with severe exacerbations and pollen sensitization. Erbas  
243 *et al.*<sup>52</sup> showed a linear increase in asthma emergency department presentations  
244 correlated with an increased concentration of ambient grain of grass pollen ( $p < 0.001$ ).  
245 More specifically, pollen-allergic children seem to be admitted due to food-induced  
246 anaphylaxis more often during the pollen season ( $p = 0.015$ )<sup>53,54</sup>.

247 In the TAP cohort “*Multiple Allergies and Severe Asthma*” phenotype includes  
248 children with a multiple allergic phenotype (100% of the children had eczema and  
249 multiple sensitizations) and higher values of IgE (1123 kU/L) and FeNO (67 ppb).  
250 Moreover, the severity of asthma is attested by the highest proportion of moderate to  
251 severe asthma (95%) and a significant decrease in FEF<sub>25-75</sub>. The clinical relevance of  
252 FeNO in asthma severity was also identified in the PIAMA cohort<sup>55</sup> and by Sonnappa  
253 *S et al*<sup>56</sup>: FeNO measured at 8 years was associated with persistent, intermediate, and

254 late-onset wheeze only in children with allergic sensitization at 8 years. The German  
255 Multicentre Allergy Study (MAS) cohort consists of 1,314 children born in 1990 and  
256 followed at the ages of 1, 3, 6, 12, 18, and 24 months and then at yearly intervals  
257 thereafter until age 13 years<sup>57</sup>. This cohort found that eczema associated with filaggrin  
258 loss-of-function mutations conveyed a greater risk of severe asthma phenotype with a  
259 significant decrease in pulmonary function at puberty. Moreover, in accordance with  
260 the TAP results, children (especially boys) with persistent wheeze, frequent asthma  
261 exacerbations, and multiple early atopy in the MAAS cohort<sup>25</sup> had diminished lung  
262 function throughout childhood and were at higher risk of a progressive loss of lung  
263 function from age 3 to 11 years. Furthermore, Garden *et al.* (the CAPS cohort)<sup>47</sup>  
264 showed that asthma risk is related to the type of allergen sensitization, with a strong  
265 association between the mixed food and inhalant sensitization class and poor asthma  
266 control at age 8 years.

267 Finally the last phenotype discovered in the TAP cohort was the “*Multiple Allergic*  
268 *Sensitizations and Mild Asthma*” phenotype, in which 97% of the children had  
269 multiple sensitizations and 100% mild asthma. Several reasons could explain this  
270 novel result linking multiple sensitizations and mild asthma severity. Firstly, this  
271 phenotype is associated with a low percentage of eczema and it is known that eczema  
272 plus allergic asthma confers an intrinsically severe asthma. Secondly, multiple allergic  
273 sensitizations could be related to biological sensitizations rather than to real allergy  
274 explaining why total IgE and FeNO values were lower in this group.

275 To summarize, severe allergic asthma in children could consist of two phenotypes  
276 depending on the type of sensitization and the association with other allergic  
277 comorbidities: severe phenotype with acute exacerbations and related to pollens and/or

278 food sensitizations and a severe phenotype with very high inflammatory markers  
279 constantly associated with atopic dermatitis.

280

### 281 *Asthma phenotypes and personalized medicine*

282 The Childhood Asthma Management Program (CAMP) is a multicenter, randomized,  
283 double-masked clinical trial designed to explore the clinical relevance of the clustering  
284 approach in assessing the long-term effects of three inhaled treatments for mild to  
285 moderate childhood asthma: budesonide (a glucocorticoid used daily) and albuterol (a  
286 short-acting  $\beta$ -agonist bronchodilator used as needed); nedocromil (a nonsteroid anti-  
287 inflammatory agent used daily) and albuterol; and placebo and albuterol<sup>11</sup>. Overall, in  
288 this cohort Howrylak *et al.*<sup>58</sup> found five reproducible patient clusters that could be  
289 differentiated on the basis of atopic burden, degree of airway obstruction, and history  
290 of exacerbation. Moreover, the clustering approach predicted long-term asthma control  
291 as well as longitudinal differences in pulmonary function and response to long term  
292 treatment.

293

### 294 *Conclusions*

295 As already suggested<sup>59</sup>, our analysis confirms that existing cohorts studies have  
296 provided data useful for the ascertainment of early life asthma phenotypes. Further  
297 studies should be designed to find noninvasive biological markers to better define  
298 wheezing phenotypes in very young children associated with an elevated risk of  
299 developing asthma to define personalized medicine based on targeted treatment.

300

301 **FIG 1: Representation of the three clusters according to the percentage of**  
302 **Multiple Trigger Wheeze, Severity and Atopy for the entire population (n=551)**

303 MTW (Multiple Trigger Wheeze) is defined as wheezing during colds and with other  
304 triggers such as house dust, grass, pets, tobacco smoke, exercise or cold air; Severity is  
305 defined as percentage of moderate to severe asthma according to GINA classification;  
306 Circled area represents the percentage of atopy defined as percentage of positive  
307 Phadiatop Infant®  $\geq 0.35$ U/ml. (Ref 14)

308

309 **FIG 2: Classification tree for entire population using two variables i.e. asthma**  
310 **severity according to GINA classification and Phadiatop Infant®**

311 Subjects are assigned to the three clusters that range from milder recurrent wheeze  
312 (Cluster 1) to more severe disease (Clusters 2 and 3) with 76% of the subject assigned  
313 to the appropriate cluster. Tree performances are given. (Ref 14)

314

315 **FIG 3: Change of wheeze phenotypes from under 3 years until 5 years of age**

316 Y axis represents change (expressed in percentage) of separate 3 clusters towards the 4  
317 clusters at 5 years of age. At 3 years of age : *Mild EVW*: Episodic Viral Wheeze  
318 (wheezing only during colds and asymptomatic between episodes), *Atopic MTW*:  
319 Multiple Trigger Wheeze (wheezing during colds and with other triggers such as  
320 house dust, grass, pets, tobacco smoke, exercise or cold air), *NAUW*: Non-atopic  
321 Uncontrolled Wheeze. The Fisher exact test rejects the independence assumption  
322 ( $p < 0.001$ ). (Ref 17)

323

324



325 **Table n° 1: Asthma phenotypes in very young children**

326

	<b>Gender Predominance</b>	<b>High risk of exacerbation</b>	<b>Prognosis in term of asthma persistence during childhood</b>	<b>Predominant inflammation /Response to corticosteroid</b>
<i>Mild Episodic Viral Wheeze</i>	<b>Male</b> <sup>18</sup>	<b>No</b> <sup>14,15,18</sup>	<b>Good</b> <sup>17,20,21,31</sup>	<b>None</b> <sup>14</sup>  <b>/High</b> <sup>14</sup>
<i>Atopic Multiple- Trigger</i>	<b>Male</b> <sup>14,21,25</sup>	<b>Yes</b> <sup>25,14,18</sup>	<b>Poor</b> <sup>14,21,17,,22,19,25,28,29</sup>  33,34,35,36	<b>Eosinophilic</b> <sup>14,18,15,19</sup>  <b>/Intermediate</b> <sup>14</sup>
<i>Nonatopic wheeze phenotype</i>	<b>Female</b> <sup>14,26</sup>	<b>No</b> <sup>14,18,15</sup>	<b>Intermediate</b>  (depending of late onset of allergic expression) <sup>17,21</sup>	<b>Neutrophilic ?</b>  <b>/Low</b> <sup>14</sup>

327

328

329 **Table n° 2: Asthma phenotypes in children at school age**

330

	<b>Gender</b>	<b>Age of asthma onset</b>	<b>High Risk of exacerbation</b>	<b>Prognosis in tem of lung function decline</b>	<b>Predominant inflammation /Response to corticosteroid</b>
<i>House dust mite Sensitization and Mild Asthma</i>	<b>M</b>	<b>Early</b> <sup>16,46,30</sup>	–	–	<b>Eosinophil /High</b> <sup>16</sup>
<i>Pollen Sensitization with Severe Exacerbations”</i>	<b>M</b>	<b>Late</b> <sup>16</sup>	<b>Yes</b> <sup>16,39</sup>	–	<b>Eosinophil</b> <sup>16,46,47,48</sup> /High <sup>16</sup>
<i>Multiple Allergic Sensitizations and eczema associated with Severe Asthma</i>	<b>M</b>	<b>Early</b> <sup>16,25,38,51</sup>	–	<b>Poor</b> <sup>16,51,45</sup>	<b>High Eosinophil</b> <sup>16,38,49</sup> /Low <sup>16</sup>
<i>Multiple Allergic Sensitizations and Mild Asthma</i>	<b>M</b>	<b>Early</b> <sup>16</sup>	–	–	<b>Eosinophil</b> <sup>16</sup> /High <sup>16</sup>
<i>Severe asthma with bronchial obstruction</i>	<b>F</b>	<b>Late</b> <sup>38,42,43,44</sup>	–	<b>Poor</b> <sup>43,44</sup>	<b>Neutrophil</b> <sup>38</sup> /Very low <sup>38,42,44</sup>

331

332

333 **References**

- 
- <sup>1</sup> Eder W, Ege MJ, von Mutius E. The asthma epidemic. *N Engl J Med* 2006;355:2226–35.
  - <sup>2</sup> McCallister JW. Reslizumab and eosinophilic asthma: one step closer to phenotype-directed therapy? *Am J Respir Crit Care Med* 2011;184:1096–7.
  - <sup>3</sup> Phelan PD, Robertson CF, Olinsky A. The Melbourne Asthma Study: 1964-1999. *J Allergy Clin Immunol*. 2002 Feb;109(2):189-94.
  - <sup>4</sup> Anderson GP. Endotyping asthma: new insights into key pathogenic mechanisms in a complex, heterogeneous disease. *Lancet* 2008;372:1107–19.
  - <sup>5</sup> Busse WW, Morgan WJ, Gergen PJ, et al. Randomized trial of omalizumab (anti-IgE) for asthma in inner-city children. *N Engl J Med* 2011 ;364 : 1015-15.
  - <sup>6</sup> A plea to abandon asthma as a disease concept. *Lancet* 2006;368:705.
  - <sup>7</sup> Arshad SH, Stevens M, Hide DW. The effect of genetic and environmental factors on the prevalence of allergic disorders at the age of two years. *Clin Exp Allergy* 1993; 23: 504-511.
  - <sup>8</sup> Bergmann RL, Bergmann KE, Lau-Schadendorf S, Luck W, Dannemann A, Bauer CP. Atopic diseases in infancy. The German multicenter atopy study (MAS-90) *Pediatr Allergy Immunol*. 1995; 5:19-25.
  - <sup>9</sup> Custovic A, Simpson BM, Murray CS, Lowe L, Woodcock A. The national asthma campaign manchester asthma and allergy study. *Pediatr Allergy Immunol* 2002; 13: 32-37.
  - <sup>10</sup> Brunekreef B, Smit J, de Jongste J, Neijens H, Gerritsen J, Postma D, Aalberse R, Koopman L, Kerkhof M, Wilga A, van Strien R. The prevention and incidence of asthma and mite allergy (PIAMA) birth cohort study: design and first results. *Pediatr Allergy Immunol*. 2002; 13: 55-60.
  - <sup>11</sup> Clarisse B, Nikasinovic L, Poinard R, Just J, Momas I. The Paris prospective birth cohort study: which design and who participates? *Eur J Epidemiol*. 2007; 22: 203-210.
  - <sup>12</sup> Boyd A, Golding J, Macleod J, Lawlor DA, Fraser A, Henderson J, Molloy L, Ness A, Ring S, Davey Smith G. Cohort Profile: the ‘children of the 90s’-the index

---

offspring of the Avon Longitudinal Study of Parents and Children. *Int J Epidemiol* 2013; 42: 111-127.

<sup>13</sup> Mahrshahi S, Peat J, Webb K, Tovey E, Marks G, Mellis C, Leeder SR. The Childhood Asthma Prevention Study (CAPS): design and research protocol of a large randomised trial of the primary prevention of asthma. *Control Clin Trials* 2001; 22:333-54.

<sup>14</sup> Spycher BD, Silverman M, Pescatore AM, Beardsmore CS, Kuehni CE. Comparison of phenotypes of childhood wheeze and cough in 2 independent cohorts *J Allergy Clin Immunol* 2013; 132: 1058-1067.

<sup>15</sup> Hovland V, Riiser A, Mowinckel P, Carlsen KH, Lødrup Carlsen KC. The significance of early recurrent wheeze for asthma outcomes in late childhood. *Eur Respir J*. 2013; 41: 838-845.

<sup>16</sup> Kauffmann F, Dizier MH. EGEA (Epidemiological study on the Genetics and Environment of Asthma, bronchial hyperresponsiveness and atopy)-design issues. EGEA Co-operative Group. *Clin Exp Allergy*. 1995; 25: 19-22.

<sup>17</sup> The Childhood Asthma Management Program (CAMP): design, rationale, and methods. Childhood Asthma Management Program Research Group. *Control Clin Trials*. 1999; 20: 91-120.

<sup>18</sup> Dolan CM, Fraher KE, Bleecker ER, Borish L, Chipps B, Hayden ML, Weiss S, Zheng B, Johnson C, Wenzel S; TENOR Study Group. Design and baseline characteristics of the epidemiology and natural history of asthma: Outcomes and Treatment Regimens (TENOR) study: a large cohort of patients with severe or difficult-to-treat asthma. *Ann Allergy Asthma Immunol*. 2004; 92: 32-39.

<sup>19</sup> American Thoracic Society Workshop. Proceedings of the ATS workshop on refractory asthma: current understanding, recommendations, and unanswered questions. *Am J Respir Crit Care Med* 2000;162: 2341–2351.

- 
- <sup>20</sup> Just J, Gouvis-Echraghi R, Couderc R, Guillemot-Lambert N, Saint-Pierre P. Two novel severe wheezy young children phenotypes: boys atopic multiple-trigger and girls non-atopic uncontrolled wheeze. *J Allergy Clin Immunol* 2012; 130: 103-110.
- <sup>21</sup> Gouvis-Echraghi R, Saint-Pierre P, Besharaty AA, Bernard A, Just J. Exhaled nitric oxide measurement confirms 2 severe wheeze phenotypes in young children from the Trousseau Asthma Program. *J Allergy Clin Immunol*. 2012; 130:1005-1007.
- <sup>22</sup> Just J, Saint-Pierre P, Gouvis-Echraghi R, Laoudi Y, Roufai L, Momas I, Annesi Maesano I. Childhood allergic asthma is not a single phenotype. *J Pediatr*. 2014; 164: 815-820.
- <sup>23</sup> Just J, Saint-Pierre P, Gouvis-Echraghi R, Boutin B, Panayotopoulos V, Chebahi N, Ousidhoum-Zidi A, Khau CA. Wheeze phenotypes in young children have different courses during the preschool period. *Ann Allergy Asthma Immunol*. 2013; 111: 256-261.
- <sup>24</sup> Herr M, Just J, Nikasinovic L, Foucault C, Le Marec AM, Giordanella JP, Momas I. Risk factors and characteristics of respiratory and allergic phenotypes in early childhood. *J Allergy Clin Immunol* 2012; 130:389-96.
- <sup>25</sup> Taussig LM, Wright AL, Morgan WJ, Harrison HR, Ray CG, Group Health Medical Associates. The Tucson Children's Respiratory Study. I. Design and implementation of a prospective study of acute and chronic respiratory illness in children. *Am J Epidemiol* 1989;129: 1219-1231.
- <sup>26</sup> Martinez FD, Wright AL, Taussig LM, Holberg CJ, Halonen M, Morgan WJ. Asthma and wheezing in the first six years of life. *N Engl J Med* 1995; 332: 133-138.
- <sup>27</sup> Spycher BD, Silverman M, Brooke AM, Minder CE, Kuehni CE. Distinguishing phenotypes of childhood wheeze and cough using latent class analysis. *Eur Respir J*. 2008; 31: 974-81.
- <sup>28</sup> Henderson J, Granell R, Heron J, Sherriff A, Simpson A, Woodcock A, Strachan DP, Shaheen SO, Sterne JA. Associations of wheezing phenotypes in the first 6 years of

---

life with atopy, lung function and airway responsiveness in mid-childhood. *Thorax* 2008; 63: 974-980.

<sup>29</sup> Mandhane PJ, Greene JM, Cowan JO, Taylor DR, Sears MR. Sex differences in factors associated with childhood- and adolescent-onset wheeze. *Am J Respir Crit Care Med* 2005; 172: 45-54.

<sup>30</sup> Sears MR, Burrows B, Flannery EM, Herbison GP, Holdaway MD. Atopy in childhood. I. Gender and allergen related risks for development of hay fever and asthma. *Clin Exp Allergy* 1993; 23: 941-948.

<sup>31</sup> Belgrave DC, Buchan I, Bishop C, Lowe L, Simpson A, Custovic A. Trajectories of lung function during childhood. *Am J Respir Crit Care Med*. 2014; 189: 1101-1109.

<sup>32</sup> Isozaki A, Shoda T, Mimura S, Ogawa N, Noma T, Kawano T, Nakamura Y, Kawano Y. A trial of hierarchical cluster analysis of hospitalized wheezy infants and young children based on clinical factors. *Arerugi* 2011; 60: 586-592.

<sup>33</sup> Rackemann FM, Mallory TB. Intrinsic Asthma. *Trans Am Clin Climatol Assoc* 1941; 57: 60-73.

<sup>34</sup> Jose A. Castro-Rodriguez, Lorena Cifuentes, Carlos E. Rodríguez-Martínez. The asthma predictive index remains a useful tool to predict asthma in young children with recurrent wheeze in clinical practice *Journal of Allergy and Clinical Immunology* 2011; 127: 1082-1083.

<sup>35</sup> Leonardi NA, Spycher BD, Strippoli MP, Frey U, Silverman M, Kuehni CE. Validation of the Asthma Predictive Index and comparison with simpler clinical prediction rules. *J Allergy Clin Immunol* 2011; 127: 1466-1472.

<sup>36</sup> Matricardi PM, Illi S, Keil T, Wagner P, Wahn U, Lau S. Predicting persistence of wheezing: one algorithm does not fit all. *Eur Respir J* 2010;35:701-3.

<sup>37</sup> Piippo-Savolainen E, Korppi M. Wheezy babies--wheezy adults? Review on long-term outcome until adulthood after early childhood wheezing. *Acta Paediatr* 2008; 97: 5-11.

---

<sup>38</sup> Stern DA, Morgan WJ, Wright AL, Guerra S, Martinez FD. Poor airway function in early infancy and lung function by age 22 years: a non-selective longitudinal cohort study. *Lancet*. 2007; 370(9589):758-64.

<sup>39</sup> Illi S, von Mutius E, Lau S, Niggemann B, Gruber C, Wahn U. Perennial allergen sensitisation early in life and chronic asthma in children: a birth cohort study. *Lancet* 2006; 368:763-70.

<sup>40</sup> Kusel MM, Keadze T, Johnston SL, Holt PG, Sly PD. Febrile respiratory illnesses in infancy and atopy are risk factors for persistent asthma and wheeze. *Eur Respir J*. 2012;39(4):876-82.

<sup>41</sup> Simpson A, Tan VYF, Winn J, Svensén M, Bishop CM, Heckerman DE, Buchan I, Custovic A. Beyond atopy: multiple patterns of sensitization in relation to asthma in a birth cohort study. *Am J Respir Crit Care Med* 2010; 181:1200-1206.

<sup>42</sup> Lazić N, Roberts G, Custovic A, Belgrave D, Bishop CM, Winn J, Curtin JA, Hasan Arshad S, Simpson A. Multiple atopy phenotypes and their associations with asthma: similar findings from two birth cohorts. *Allergy*. 2013; 68: 764-70.

<sup>43</sup> From the Global Strategy for Asthma Management and Prevention, Global Initiative for Asthma (GINA) 2009. Available from: <http://www.ginasthma.org>, Date last update June 9 2014. Date last accessed June 9 2014

<sup>44</sup> Just J, Gouvis-Echraghi R, Rouve S, Wanin S, Moreau D, Annesi-Maesano I. Two novel, severe asthma phenotypes identified during childhood using a clustering approach. *Eur Respir J* 2012; 40: 55-60.

<sup>45</sup> Carroll WD, Lenney W, Child F, Strange RC, Jones PW, Whyte MK, Primhak RA, Fryer AA. Asthma severity and atopy: how clear is the relationship? *Arch Dis Child* 2006; 91: 405-409.

<sup>46</sup> Wang F, He XY, Baines KJ, Gunawardhana LP, Simpson JL, Li F, Gibson PG. Different inflammatory phenotypes in adults and children with acute asthma. *Eur Respir J* 2011; 38: 567-574.

---

<sup>47</sup> The ENFUMOSA cross-sectional European multicentre study of the clinical phenotype of chronic severe asthma. European Network for Understanding Mechanisms of Severe Asthma. *Eur Respir J* 2003; 22: 470-477.

<sup>48</sup> Siroux V, Basagaña X, Boudier A, Pin I, Garcia-Aymerich J, Vesin A, Slama R, Jarvis D, Anto JM, Kauffmann F, Sunyer J. Identifying adult asthma phenotypes using a clustering approach. *Eur Respir J*. 2011; 38: 310-317.

<sup>49</sup> Moore WC, Hastie AT, Li X, Li H, Busse WW, Jarjour NN, Wenzel SE, Peters SP, Meyers DA, Bleecker ER; National Heart, Lung, and Blood Institute's Severe Asthma Research Program. Sputum neutrophil counts are associated with more severe asthma phenotypes using cluster analysis. *J Allergy Clin Immunol*. 2014; 133: 1557-1563.

<sup>50</sup> Moore WC, Meyers DA, Wenzel SE, Teague WG, Li H, Li X, D'Agostino R Jr, Castro M, Curran-Everett D, Fitzpatrick AM, Gaston B, Jarjour NN, Sorkness R, Calhoun WJ, Chung KF, Comhair SA, Dweik RA, Israel E, Peters SP, Busse WW, Erzurum SC, Bleecker ER; National Heart, Lung, and Blood Institute's Severe Asthma Research Program. Identification of asthma phenotypes using cluster analysis in the Severe Asthma Research Program. *Am J Respir Crit Care Med* 2010; 181: 315-323.

<sup>51</sup> Garden FL, Simpson JM, Marks GB; CAPS Investigators. Atopy phenotypes in the Childhood Asthma Prevention Study (CAPS) cohort and the relationship with allergic disease: clinical mechanisms in allergic disease. *Clin Exp Allergy*. 2013; 43: 633-641.

<sup>52</sup> Erbas B, Akram M, Dharmage SC, Tham R, Dennekamp M, Newbigin E, Taylor P, Tang ML, Abramson MJ. The role of seasonal grass pollen on childhood asthma emergency department presentations. *Clin Exp Allergy* 2012; 42: 799-805.

<sup>53</sup> Vetander M, Helander D, Flodström C, Ostblom E, Alfvén T, Ly DH, Hedlin G, Lilja G, Nilsson C, Wickman M. Anaphylaxis and reactions to foods in children--a population-based case study of emergency department visits. *Clin Exp Allergy* 2012; 42: 568-577.

<sup>54</sup> Katelaris CH. Food allergy and oral allergy or pollen-food syndrome. *Curr Opin Allergy Clin Immunol* 2010; 10: 246-251.



- 
- <sup>55</sup> van der Valk RJ, Caudri D, Savenije O, Koppelman GH, Smit HA, Wijga AH, Postma DS, Kerkhof M, Brunekreef B, de Jongste JC. Childhood wheezing phenotypes and FeNO in atopic children at age 8. *Clin Exp Allergy*. 2012; 42: 1329-1336.
- <sup>56</sup> Sonnappa S, Bastardo CM, Saglani S, Bush A, Aurora P. Relationship between past airway pathology and current lung function in preschool wheezers. *Eur Respir J*. 2011; 38: 1431-1436.
- <sup>57</sup> Marenholz I, Kerscher T, Bauerfeind A, Esparza-Gordillo J, Nickel R, Keil T, Lau S, Rohde K, Wahn U, Lee YA. An interaction between filaggrin mutations and early food sensitization improves the prediction of childhood asthma. *J Allergy Clin Immunol* 2009; 123: 911-916.
- <sup>58</sup> Howrylak JA, Fuhlbrigge AL, Strunk RC, Zeiger RS, Weiss ST, Raby BA; Childhood Asthma Management Program Research Group. Classification of childhood asthma phenotypes and long-term clinical responses to inhaled anti-inflammatory medications. *J Allergy Clin Immunol*. 2014; 133: 1289-1300.
- <sup>59</sup> Bousquet J, Gern JE, Martinez FD, Anto JM, Johnson CC, Holt PG, Lemanske RF Jr, Le Souëf PN, Tepper RS, von Mutius ER, Arshad SH, Bacharier LB, Becker A, Belanger K, Bergström A, Bernstein DI, Cabana MD, Carroll KN, Castro M, Cooper PJ, Gillman MW, Gold DR, Henderson J, Heinrich J, Hong SJ, Jackson DJ, Keil T, Kozyrskyj AL, Lødrup Carlsen KC, Miller RL, Momas I, Morgan WJ, Noel P, Ownby DR, Pinart M, Ryan PH, Schwaninger JM, Sears MR, Simpson A, Smit HA, Stern DA, Subbarao P, Valenta R, Wang X, Weiss ST, Wood R, Wright AL, Wright RJ, Togias A, Gergen PJ. Birth cohorts in asthma and allergic diseases: report of a NIAID/NHLBI/MeDALL joint workshop. *J Allergy Clin Immunol*. 2014; 133: 1535-1546.






Fig. 1

Fig. 2



Population		Prediction		
		1	2	3
Cluster label	1	<b>70</b>	10	0
	2	1	<b>53</b>	1
	3	14	2	<b>16</b>

Percentage		Prediction		
		1	2	3
Cluster label	1	<b>0.88</b>	0.12	0
	2	0.02	<b>0.96</b>	0.02
	3	0.44	0.06	<b>0.5</b>






Fig. 3